Semaglutide for Treating Obesity Induced by Craniopharyngioma Resection: A Successful Case Study.

Sciacovelli C, Moschione G, Garelli S, Pagotto U

JCEM case reports27 Jul 2023Cited by 15 (Europe PMC)

PMID37908981PMCIDPMC10580492DOI10.1210/jcemcr/luad074PepBankPUB-37908981

Summary

Surgical treatment of craniopharyngioma often leads to a rapid and dramatic weight gain, leading to hypothalamic obesity. Treatment focused on the diet, physical activity, and different types of drugs have very often provided unsatisfactory results. To date, no data have been reported on hypothalamic obesity (HO) regarding the use of semaglutide, a novel type 1 receptor glucagon-like peptide-1 agonist, to limit body weight gain after surgical removal of a neoplasm, despite its already documented efficacy in obesity treatment. In this case report, we tested semaglutide in an 18-year-old patient with HO induced by a surgical intervention for craniopharyngioma. A very favorable treatment response was found in terms of body weight reduction and improvement in metabolic parameters. Our patient lost more than than 30 kg after only 6 months of therapy, which has never been reported before in the literature on HO.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

01HumanCase report or seriesEfficacy outcome
In an 18-year-old with hypothalamic obesity after craniopharyngioma surgery, semaglutide was followed by a loss of more than 30 kg in 6 months.
In plain wordsIn one 18-year-old with obesity after brain tumor surgery, semaglutide was followed by a loss of more than 30 kg in 6 months.
Peptide
Semaglutide
Outcome
DecreaseBody weight loss
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Weight loss
> 30 kg
after 6 months
Source sentences
Summary
Our patient lost more than than 30 kg after only 6 months of therapy, which has never been reported before in the literature on HO.
1 context sentence(design, population, supporting numbers)
Summary · context
In this case report, we tested semaglutide in an 18-year-old patient with HO induced by a surgical intervention for craniopharyngioma.
Show in the study text Report a problemFND-3790898101
02HumanCase report or seriesEfficacy outcome
In an 18-year-old with hypothalamic obesity after craniopharyngioma surgery, metabolic parameters improved with semaglutide.
In plain wordsIn one 18-year-old with obesity after brain tumor surgery, metabolic measures improved while on semaglutide.
Peptide
Semaglutide
Outcome
Direction not reportedMetabolic parameters
Study
n = 1
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
A very favorable treatment response was found in terms of body weight reduction and improvement in metabolic parameters
1 context sentence(design, population, supporting numbers)
Summary · context
In this case report, we tested semaglutide in an 18-year-old patient with HO induced by a surgical intervention for craniopharyngioma.
Show in the study text Report a problemFND-3790898102

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.